Close Menu

NEW YORK (360Dx) – Quest Diagnostics' decision to move to a new cholesterol calculation method will give physicians more accurate readings of "bad cholesterol" when treating high risk patients, the company said.

Quest announced its decision last month to move to the new nonfasting cholesterol test, which relies on a new calculation method that replaces the Friedewald equation, the standard cholesterol test in laboratories in the US since 1972.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.